Unravelling the mystery of the TACT trial.
Martin
Miguel
M
Medical Oncology Department, Hospital Clinico San Carlos, Madrid 28040, Spain. mmartin@geicam.org
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D017024:Chemotherapy, Adjuvant; D017326:Clinical Trials, Phase III as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D015251:Epirubicin / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D043823:Taxoids / Q000627:therapeutic use*; D006113:United Kingdom / Q000453:epidemiology
D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D015251:Epirubicin; D003520:Cyclophosphamide; D005472:Fluorouracil